These data suggest beneficial effects of decreased neuronal insulin/IGF-1 signaling on Alzheimer-pathology and question the therapeutic outcome of long-term administration of insulin or IGF-1 in patients with AD (Zemva and Schubert, 2014). This evidence concerns the gene IGF1 and Alzheimer disease.